Risk factors

Clinical-stage pharmaceutical company with no revenue, relying heavily on financing and government grants to survive.

Escalade faces intense sporting goods competition and relies heavily on two major customers accounting for over ten percent of sales.

Gaia faces risks primarily from intense streaming competition, reliance on proprietary technology and internet delivery, and international expansion challenges.

Specialty finance exposure is prominent, including factoring, equipment finance, merchant cash advances, hard-money real estate lending, and 13.3% of investments.

The company relies heavily on Solasglas for investment performance managed exclusively by DME Advisors.

HighPeak Energy faces substantial risks from its $1.1 billion total debt maturing in 2026 and commodity price volatility. Operations depend heavily on horizontal drilling execution, third-party midstream facilities, and water and frac sand availability.

KVH Industries faces intense competitive disruption from Starlink and LEO services transitioning customers away from traditional geosynchronous satellite communications. The company is winding down its Middletown manufacturing facility by the end of 2025 to rely on third-party hardware. High reliance on international markets, representing 73% of 2024 revenue, creates significant foreign regulatory and currency exposure.

Company is heavily reliant on Roche for OpRegen development and revenue.

Dependence on the ODR segment growth strategy drives overall business success. Management of labor costs, union relations, and subcontractor networks is critical. Exposure to fixed-price contract risks and material cost inflation heavily impacts profitability.

MetroCity Bankshares faces geographic concentration risks across seven states and heavy exposure to real estate collateral. The bank relies significantly on customer deposits, non-conforming residential mortgages, and targeted demographic marketing to Asian-American communities.

Maiden Holdings faces ongoing operating losses with a 2024 net loss of $201.0 million driven by legacy reserve development.

Myomo faces ongoing operating losses with an accumulated deficit of $103.1 million, while relying heavily on direct billing and Medicare Advantage reimbursement for its MyoPro device.